Literature DB >> 1675283

Antidiuretic effect of bremazocine and U-50,488 in rats after alpha 2-adrenoceptor blockade.

G Bianchi1.   

Abstract

The role of alpha 2-adrenoceptors and kappa-opioid receptors in urination was studied in rats. In water-loaded rats (40 mL kg-1 p.o.) the kappa-opioid agonist bremazocine (0.05 0.2 mg kg-1 i.p.) induced a dose-related diuretic response in the second hour after administration, but had no effect in the first hour. When rats were pretreated with the alpha 2-adrenoceptor antagonist idazoxan (1 mg kg-1 s.c.), bremazocine induced a dose-related antidiuretic response in the first hour; thereafter the rats showed an increase of urination similar to that with bremazocine alone. The antidiuretic effect of bremazocine was dependent on the dose of idazoxan with maximal response after 1-3 mg kg-1. Similar results were obtained with bremazocine in the presence of yohimbine (1 mg kg-1 s.c.). The antidiuretic profile of bremazocine after idazoxan was shared by U-50,488 (2.5-10 mg kg-1 i.p.), although this compound alone at the high dose reduces urine output in the first hour. The antidiuresis induced by bremazocine in the presence of idazoxan in water-loaded rats was completely antagonized by 10 but not 2 mg kg-1 i.p. of the opioid antagonist naloxone. Thus, kappa-opioid agonists, in addition to their diuretic effect, also produce an antidiuretic response which may be mediated by alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675283     DOI: 10.1111/j.2042-7158.1991.tb06670.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  The effects of idazoxan and other alpha 2-adrenoceptor antagonists on urine output in the rat.

Authors:  H C Jackson; I J Griffin; S D Birkett; D J Nutt
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  Central and peripheral actions of the novel kappa-opioid receptor agonist, EMD 60400.

Authors:  A Barber; G D Bartoszyk; H E Greiner; F Mauler; R D Murray; C A Seyfried; M Simon; R Gottschlich; J Harting; I Lues
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.